Characteristics of studies used to support FDA lung cancer approvals (2006 to 2018) made via the accelerated vs regular pathways and BTD vs non-BTD.

Characteristics of studies used to support FDA lung cancer approvals (2006 to 2018) made via the accelerated vs regular pathways and BTD vs non-BTD.2006年至2018年间，用于支撑美国食品药品监督管理局（Food and Drug Administration，FDA）肺癌适应症获批的研究特征，相关获批分别通过加速审批通道与常规审批通道、突破性疗法认定（Breakthrough Therapy Designation，BTD）与非突破性疗法认定路径完成。